Roche’s gantenerumab fails to meet primary endpoint in AD trial
Roche’s investigational medicine gantenerumab has failed to achieve its primary endpoint in the Phase II/III Alzheimer’s disease (AD) trial.
Roche’s investigational medicine gantenerumab has failed to achieve its primary endpoint in the Phase II/III Alzheimer’s disease (AD) trial.
Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million (approximately USD 28 million).
X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEX) drug discovery platform to the generation of novel small molecule therapeutics, announced a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment of allergies.
Genprex, a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, provides a clinical update and focus for its Oncoprex immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).
Aimmune Therapeutic has secured exclusive worldwide rights to Xencor’s XmAb 7195 for the development of next-generation food allergy treatments.
Regeneron Pharmaceuticals has expanded its collaboration with the US Department of Health and Human Services (HHS) to develop antibody treatments for novel coronavirus (2019-nCoV).
Bristol-Myers Squibb (BMS) and BioMotiv have launched a new biotechnology company, Anteros Pharmaceuticals, which will involve in the development of a new class of drugs for fibrotic and other inflammatory diseases.
US-based Catalent has agreed to acquire cell therapy company MaSTherCell Global for $315m in cash.
British drugmaker GlaxoSmithKline (GSK) has collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the novel Coronavirus (2019-nCoV).
Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak.